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Platelet-activating factor (PAF) is a potent lipid mediator
that exhibits versatile biologic activities in many diverse
systems by binding to a specific cell-surface receptor
(PAFR). Although the production of PAF in cultured
keratinocytes and fibroblasts has been reported, physiol-
ogic roles of this mediator in skin remain unclear. In this
study, we examined in situ expression of PAFR gene in
rat skin and the effects of PAF on the proliferation and
differentiation of cultured human keratinocytes. In rat
epidermis, PAFR mRNA expression was found from the
basal cells to the granular cells, and strong signals were
seen in the stratum spinosum. In cultured human ker-
atinocytes, a 3.8 kb PAFR mRNA expression was demon-
strated by northern blotting, and two distinct type
transcripts driven by different promoters were detected by
reverse transcriptase polymerase chain reaction analysis.
Platelet-activating factor (1–0-alkyl-2-acetyl-sn-glycero-3-phosphocholine; PAF) is a potent phospholipid mediatorof acute allergic and inflammatory reactions, which causesmicrovascular leakage, vasodilatation, contraction ofsmooth muscle, and activation of neutrophils, macrophages,
and eosinophils (Hanahan, 1986; Prescott et al, 1990; Izumi and
Shimizu, 1995). It has been shown that PAF is involved not only in
inflammation but also in physiologic processes of diverse systems, such
as cardiovascular (Rayner et al, 1991; Massey et al, 1991), reproductive
(O’Neill, 1992; Baldi et al, 1994), and central nervous systems (Kato
et al, 1994; Mori et al, 1996).
In skin, it has been suggested that PAF is involved in some diseases
such as psoriasis (Mallet et al, 1984; Mallet and Cunningham, 1985),
cold urticaria (Grandel et al, 1985), urticaria pigmentosa (Guinot et al,
1988), and contact dermatitis (Lavaud et al, 1991). Both cultured
human keratinocytes (Michel et al, 1990; Travers et al, 1996) and skin
fibroblasts (Michel et al, 1988) have been shown to produce PAF;
however, the roles of PAF in normal skin remain unknown.
The actions of PAF are mediated through the activation of a
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Addition of PAF (30–100 nM) to cultured keratinocytes
during a growth phase inhibited the proliferation. This
effect was receptor dependent, because the inhibition
was completely blocked by a PAFR antagonist, WEB
2086 (100 nM). On the other hand, whereas PAF (30–
100 nM) alone did not affect the cornified envelope
formation during the process of keratinocyte differenti-
ation, WEB 2086 (30–300 nM) accelerated it in a concen-
tration-dependent manner. Addition of PAF (100 nM)
reversed the effect of WEB 2086, suggesting that WEB
2086 induced cornification by inhibiting PAF endogene-
ously produced by keratinocytes in an autocrine manner.
Thus, we propose that PAF is an intrinsic regulator of
keratinocyte during proliferation and differentiation. Key
words: cornified envelope/PAFR antagonist/WEB 2086. J Invest
Dermatol 110:889–893, 1998
G protein-coupled seven transmembrane spanning receptor (PAFR)
(Honda et al, 1991; Chao and Olson, 1993; Izumi and Shimizu, 1995).
PAFR cDNA of guinea pig (Honda et al, 1991), human (Nakamura
et al, 1991; Ye et al, 1991; Kunz et al, 1992; Sugimoto et al, 1992),
and rat (Bito et al, 1994), and a PAFR gene of mouse (Ishii et al,
1996), have been cloned. Studies on human cDNA and genome
showed that the human PAFR gene generates two different species of
mRNA (PAFR transcript 1 and PAFR transcript 2), whose expression
is driven by distinct promoters (Mutoh et al, 1993). The distributions
of these two transcripts are different. PAFR transcript 1 is found
ubiquitously, and is most abundant in peripheral leukocytes and a
human eosinophilic cell line (EoL-1 cells), whereas the PAFR transcript
2 is detected in the heart, lung, spleen, and kidney, but not in
leukocytes, EoL-1 cells, or brain. Immunohistochemical and radioligand
binding studies showed that functional PAFR are present in various
cells and tissues, including human keratinocytes (Travers et al, 1995).
Recently, we reported that PAFR-overexpressing transgenic mice
showed an aberrant melanogenesis and proliferative abnormalities in
both epidermis and dermis (Ishii et al, 1997). Our findings provide
new insights regarding the roles of PAF in the skin in vivo.
In this study, we demonstrated that PAFR mRNA is expressed in
the epidermis and the expression in human keratinocytes is driven by
two distinct promoters. We also examined the effects of PAF on the
proliferation and differentiation of cultured human keratinocytes.
MATERIALS AND METHODS
Materials Human normal epidermal keratinocytes, melanocytes, bovine pitu-
itary extracts (BPE), and human melanocyte growth supplement were obtained
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from Kurabo (Osaka, Japan), human skin fibroblasts (Detroit 551) were from
American Type Culture Collection (Rockville, ME: ATCC No. CCL110), and
male WBN/ILA-HT rats were from Ishikawa Laboratory Animal (Saitama,
Japan). Eagle’s minimum essential medium, nonessential amino acids, and
sodium pyruvate were obtained from Dainippon Pharmaceutical (Osaka, Japan),
fetal bovine serum was from JRH Biosciences (Lenexa, KS), and MCDB153
medium, calcium ionophore A23187, and bovine insulin were from Wako
Pure Chemical Industries (Osaka, Japan). Epidermal growth factor was purchased
from Sigma (Tokyo, Japan), hydrocortisone from Merck (Darmstadt, Germany),
2-aminoethanol from Nacalai Tesque (Kyoto, Japan), and o-phosphorylethanola-
mine from Tokyo Kasei Kogyo (Tokyo, Japan). Oligotex-dT30 was obtained
from TaKaRa Shuzou (Kyoto, Japan), digoxigenin (DIG) RNA labeling kit,
DIG nucleic acid detection kit, proteinase K, and positively charged nylon
membranes were from Boehringer (Mannheim, Germany), RNaid Kit was
from Bio101 (Vista, CA), human glyceraldehyde-3-phosphate dehydrogenase
(G3PDH) cDNA was from Clontech (Palo Alto, CA), SuperScript II RNase
H– Reverse Transcriptase was from Gibco BRL (Rockville, MD), oligo d(T)16
was from Perkin Elmer Japan (Chiba, Japan), and SYBR Green I nucleic acid
gel stain was from FMC BioProducts (Rockland, ME). PAF and methylcarba-
moyl-PAF (1-hexadecyl-2-N-methylcarbamoyl-glycerophosphocholine; c-PAF)
were obtained from Cayman Chemical (Ann Arbor, MI). WEB 2086 (Casals-
Stenzel, 1987) was a gift from Dr. Iemura (New Drug Discovery Research
Laboratory, Kanebo Ltd). SM10661 (Komuro et al, 1990), CV-3988 (Terashita
et al, 1985), U66985 (Tokumura et al, 1985), and FR-49175 (Okamoto et al,
1986) were obtained from Funakoshi (Tokyo, Japan).
In situ mRNA hybridization In situ mRNA hybridization was performed
as described previously with some modifications (Igarashi et al, 1995). In brief,
paraformaldehyde-fixed, paraffin-embedded skin tissues from male hairless rats
(WBN/IIA-HT; 6 wk old) were sectioned at a thickness of 5 µm, mounted
on silane-coated slides, deparaffinized, and treated with 0.2 N HCl for 20 min
followed by 10 µg proteinase K per ml digestion at 37°C for 10 min. Sections
were postfixed with 4% paraformaldehyde in phosphate buffered saline for
20 min, treated twice with phosphate buffered saline containing 2 mg glycine
per ml for 15 min, and acetylated with 0.25% acetic anhydride in triethanolamine
buffer (pH 8.0) for 10 min.
A DIG-labeled rat PAFR anti-sense RNA probe (331 bases) was prepared
from the cDNA (Bito et al, 1994) between BstPI and PstI sites using T7 RNA
polymerase with a DIG RNA-labeling kit according to the manufacture’s
instructions. DIG-labeled RNA probes (final 1 µg per ml) in 10 mM Tris/HCl
buffer (pH 8.0) containing 50% formamide, 10% dextran sulfate, 1 3 Denhardt’s
solution, 250 µg tRNA per ml, 4 3 sodium citrate/chloride buffer (SSC;
0.6 M NaCl, 0.06 M trisodiumcitrate), 0.02% sodium dodecyl sulfate (SDS),
0.1% lauroylsarcosine, and 2% blocking reagent (Boehringer) were placed on
the slides. In control experiments, an excess amount of nonlabeled rat PAFR
anti-sense RNA (final 100 µg per ml) or nonlabeled mouse hyaluronan synthase
1 (Itano and Kimata, 1996) anti-sense RNA (353 bases, final 100 µg per ml)
corresponding to the cDNA between BamHI and EcoRI sites was added to the
mixture. Hybridization was performed in a humidified chamber at 46°C for
18 h, and the sections were washed at 46°C in 2 3 SSC with 50% formamide
for 30 min, in 2 3 SSC for 20 min, and twice in 0.2 3 SSC for 20 min. After
a post-hybridization washing, DIG-labeled probes were visualized with 5-
bromo-4-chloro-3-indolylphosphate and nitroblue tetrazolium chloride with a
DIG nucleic acid detection kit according to the manufacturer’s instructions.
Cell culture Human epidermal keratinocytes, melanocytes, and skin
fibroblasts were seeded in 90 mm dishes coated with mouse type 1 collagen,
225 cm2 flasks, and 75 cm2 flasks (Falcon), respectively. Keratinocytes were
routinely grown in MCDB153 (0.1 mM Ca11) supplemented with 5 mg
bovine insulin per liter, 180 µg hydrocortisone per liter, 6.0 mg 2-aminoethanol
per liter, 14.1 mg o-phosphorylethanolamine per liter, 100 ng epidermal growth
factor per liter, and 0.4% (vol/vol) BPE. Melanocytes were cultured in
MCDB153 supplemented with 1% human melanocyte growth supplement, and
fibroblasts in minimum essential medium supplemented with 10% (vol/vol)
fetal bovine serum, 1% nonessential amino acids, and 1 mM sodium pyruvate.
Subconfluent cells were harvested for RNA extraction.
Northern blotting analysis Total RNA and poly (A)1 RNA were isolated
using an RNaid Kit and Oligotex-dT30, sequentially. Equal amounts of poly
(A)1 RNA samples (5 µg per lane) were separated by electrophoresis on a 0.8%
formaldehyde/agarose gel and transferred onto a nylon membrane. A DIG-
labeled human PAFR anti-sense RNA probe (1.1 kb) was prepared from the
cDNA (Nakamura et al, 1991) between EcoRI and Smal sites using T7 RNA
polymerase as described above.
The membrane was prehybridized in 50 mM sodium phosphate buffer
(pH 7.0) containing 5 3 SSC, 50% formamide, 7% SDS, 2% blocking reagent,
0.1% lauroylsarcosine, and 50 µg yeast RNA per ml. Hybridization was
performed at 68°C for 16 h in the same solution in the presence of DIG-
labeled human PAFR anti-sense RNA probe (50–100 ng per ml). The
membrane was then washed twice at room temperature for 5 min in 2 3 SSC
and 0.1% SDS, and twice at 68°C for 20 min in 0.1 3 SSC and 0.1%
SDS. Chemiluminescence was detected as described previously (Engler-Blum
et al, 1993).
A DIG-labeled human G3PDH anti-sense RNA probe was prepared from
the cDNA using T7 RNA polymerase as described above. The membrane was
washed at 95°C for 3 min in 0.1% SDS, cooled to a room temperature, and
rehybridized with DIG-labeled human G3PDH anti-sense RNA probe.
Reverse transcriptase-polymerase chain reaction (RT-PCR) Total RNA
(2 µg) was transcribed with SuperScript II RNase H– Reverse Transcriptase
into cDNA using oligo d(T)16 as primers and the cDNA was then used for
PCR. PCR primers used were C1 (59-CCCGAGCACAAAGATGATGC-39,
complementary to nucleotide 187 to 168 of exon 3) (Nakamura et al, 1991),
in combination with either L1 (59-GGCTGGGGCCAGGACCCAGA-39,
nucleotide –104 to –85 of exon 1) (Nakamura et al, 1991), or H1 (59-
CCTGAGCTCCCCGAGAAGTCA-39, nucleotide –165 to –145 of exon 2)
(Sugimoto et al, 1992). Amplified fragments were analyzed by agarose gel
electrophoresis and stained by SYBR Green I nucleic acid gel stain.
Measurement of proliferation Keratinocytes (1 3 104 cells per well) were
seeded in 24 well plates coated with mouse type I collagen (Falcon), cultured
for 1 d prior to the addition of PAF (30–100 nM) and/or WEB 2086 (100 nM),
and cultured for another 3 d under the conditions as described above except
for supplement with 0.04% (vol/vol) BPE and epidermal growth factor-free.
After collecting cells by trypsinization, the numbers of cells negative for trypan
blue staining were counted with a hemacytometer.
Measurement of the ratio of cornified envelope formation At 4 d after
being seeded as described above, PAF (30–100 nM) and/or WEB 2086 (30–
300 nM) was added to keratinocytes, and the cells were cultured for a further
7 d under the conditions as described above except for supplement with 0.04%
(vol/vol) BPE. After collecting cells by trypsinization, the numbers of total cells
were counted with a hemacytometer. Then, the cells were incubated at 37°C
for 2 h in the MCDB153 medium containing 1.25 mM CaCl2 and 20 µg
A23187 per ml. After aspirating the medium, the cells were boiled for 5 min
in 100 µl of 1% SDS containing 20 mM dithiothreitol. The numbers of
remaining cells, which were resistant to SDS because of their cornified envelope
formation, were counted. The ratio of insoluble cells to total cells was calculated
and regarded as the ratio of cornified envelope formation.
RESULTS
PAFR mRNA is expressed in rat skin We examined the expression
of PAFR mRNA in rat skin by in situ mRNA hybridization technique
(Fig 1). In the epidermis, hybridization signals were detected from the
basal to granular cells, and hair follicles. Some strong signals were seen
in the stratum spinosum. In the dermis, signals were seen in some
fibroblast-like cells (Fig 1a).
The signals derived from the DIG-labeled rat PAFR anti-sense RNA
probe were specific because a 100-fold excess amount of nonlabeled
PAFR anti-sense RNA markedly decreased the signals from DIG-
labeled PAFR probe (Fig 1b), whereas an excess amount of nonlabeled
mouse hyaluronan synthase 1 anti-sense RNA without any homology
to the sequence of the rat PAFR anti-sense RNA probe, did not
decrease the signals (Fig 1c).
PAFR mRNA is expressed in cultured human skin
keratinocytes Poly (A)1 RNA samples prepared from subconfluent
cells were analyzed by northern blotting using a DIG-labeled human
PAFR anti-sense RNA probe (Fig 2). PAFR mRNA was detected
only in keratinocytes as a single band with a size of 3.8 kb (Fig 2, lane
1). The size of mRNA was the same as that detected in human
peripheral blood leukocytes, a positive control for expression of
PAFR mRNA (data not shown). Accumulation of PAFR mRNA in
keratinocytes was about one-tenth of the peripheral blood leukocytes
when the density of the bands was analyzed using NIH Image (available
by anonymous ftp from zippy.nimh.nih.gov; data not shown). PAFR
mRNA was not detected in melanocytes (Fig 2, lane 2) or fibroblasts
(Fig 2, lane 3). The integrity of RNA samples was tested by using a
human G3PDH anti-sense RNA probe. G3PDH mRNA as an internal
standard was detected in all cells as a single band with a size of
1.3 kb (Fig 2).
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Figure 1. In situ expression of PAFR mRNA in rat skin. Hybridization
was performed (a) with a DIG-labeled rat PAFR anti-sense RNA probe, (b)
with the same probe in the presence of an excess amount of nonlabeled rat
PAFR anti-sense RNA, and (c) with the same probe in the presence of an
excess amount of nonlabeled mouse hyaluronan synthase 1 anti-sense RNA.
Scale bars, 50 µm.
Cultured human keratinocytes express two distinct forms of
PAFR mRNA To examine the expression of two distinct forms of
transcripts in cultured human keratinocytes, RT-PCR was carried out.
Either L1/C1 (Fig 3, left) or H1/C1 (Fig 3, right) primer combination
generated significant amplification products of 191 or 252 bp, corres-
ponding to PAFR transcript 1 and 2, respectively. The latter combina-
tion, i.e., transcript 2, yielded relatively more product.
PAF inhibits keratinocyte proliferation Next, we examined the
effects of PAF on the proliferation of cultured human keratinocytes
(Fig 4). PAF (30–100 nM) inhibited the proliferation of keratinocytes
Figure 2. Expression of PAFR mRNA in cultured human keratinocytes.
Equal amounts of poly (A)1 RNA (5 µg per lane) extracted from keratinocytes
(lane 1), melanocytes (lane 2), and fibroblasts (lane 3) were used for northern
blotting analysis. The chemiluminescent signals were detected by exposure to
a X-ray film for 30 min. After stripping of PAFR anti-sense RNA probes,
rehybridization was performed with DIG-labeled G3PDH anti-sense RNA
probe.
Figure 3. RT-PCR analysis for expression of two forms of transcripts
in cultured human keratinocytes. Amplification products from keratinocytes
using the promoter-pairs L1/C1 (left) and H1/C1 (right) were examined by
separation in agarose gels. Both 191 bp and 252 bp fragments derived from
PAFR transcripts 1 and 2, respectively, were detected.
Figure 4. Inhibitory effects of PAF on the proliferation of keratinocytes.
Keratinocytes were cultured with PAF and/or WEB 2086 for 3 d. Cells were
trypsinized and counted. Mean 6 SEM, n 5 3, **p , 0.01 (Dunnett’s test).
at a growth phase. Inhibitory effects of PAF (100 nM) were blocked
by a specific PAFR antagonist, WEB 2086 (100 nM). These observations
indicate that PAF inhibits keratinocyte proliferation via the specific
PAFR. c-PAF (100 nM), a metabolically stable analog of PAF, also
inhibited keratinocyte proliferation, and the effect was blocked by
WEB 2086 (100 nM) as similar to PAF (data not shown).
WEB 2086 stimulates the cornified envelope formation of
keratinocytes We determined the effects of PAF on the differenti-
ation of cultured human keratinocytes. Exogenous addition of PAF
(30–100 nM) had no effects on cornified envelope formation by itself,
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Figure 5. Accerelating action of WEB 2086 on the cornified envelope
formation of keratinocytes and inhibitory effect of exogenous PAF. The
ratio of cornified envelope formation was calculated as described in Materials
and Methods. Error bars, mean 6 SEM, n 5 3, **p , 0.01 (Dunnett’s test).
Figure 6. Concentration-dependent effects of WEB 2086 on the cornified
envelope formation of keratinocytes. The ratio of cornified envelope
formation was calculated as described in Materials and Methods. Error bars, mean
6 SEM, n 5 3, *p , 0.05, **p , 0.01 (Dunnett’s test).
but PAF reversed the stimulatory action of WEB 2086 (100 nM)
(Fig 5). Furthermore, WEB 2086 (30–300 nM) accelerated the
cornified envelope formation of keratinocytes in a concentration-
dependent manner (Fig 6). These results can be explained by the
fact that WEB 2086 stimulates the cornified envelope formation of
keratinocytes by antagonizing endogenously produced PAF. Essentially
similar results were obtained using c-PAF (100 nM) (data not shown).
Other PAFR antagonists also reinforced the cornification of ker-
atinocytes. The proportions of the cornified envelope formation on
addition of 30 nM FR-49175, 100 nM U66985, 100 nM CV-3988,
and 300 nM SM-10661 were increased by 1.63-, 1.56-, 1.56-, and
1.26-fold more than control, respectively.
DISCUSSION
In this study, we demonstrated epidermal expression of PAFR mRNA
by in situ hybridization (Fig 1) and northern blotting analysis (Fig 2).
Our studies agree with the previous report that functional PAFR
are present on the membranes of cultured human keratinocytes as
determined by immunohistochemical and radioligand binding experi-
ments (Travers et al, 1995). They also reported that PAFR is most
intensely localized on the suprabasal cells in human skin. In rat
epidermis, the expression of PAFR mRNA was strongest in the stratum
spinosum (Fig 1a), and beneath the stratum corneosum in mouse
epidermis (data not shown). Signals for PAFR mRNA were seen in
some fibroblast-like cells in rat (Fig 1a) and mouse (data not shown)
dermis, but on northern blotting analyses the signals were not detected
in cultured human fibroblasts (Fig 2, lane 3). Differences in species,
growth phase, cell type, and culture conditions, which markedly
influence the expression of PAFR mRNA, may explain the discrepancy
(Nakamura et al, 1991; Kunz et al, 1992; Bito et al, 1994; Izumi et al,
1995; Ishii et al, 1996).
Moreover, we examined the expression of two distinct forms of
transcripts in cultured human keratinocytes. RT-PCR study indicates
that cultured human keratinocytes express both transcripts, PAFR
transcript 1 and PAFR transcript 2 (Fig 3). Northern blotting analyses
showed that transforming growth factor-β (10 ng per ml) downregulated
the expression of PAFR mRNA, whereas interferon-γ (10 ng per ml)
upregulated the expression in cultured human keratinocytes (data not
shown). These results are consistent with results from RT-PCR
analyses, because the promoter region for the PAFR transcript 2
contains a consensus sequence for transforming growth factor-β inhibit-
ory element (Mutoh et al, 1993), and because interferon-γ upregulates
PAFR gene expression in human monocytes (Ouellet et al, 1994).
These suggest that the PAFR gene expression in keratinocytes is
regulated by a dual promoter system.
As keratinocytes highly expressed PAFR, we investigated the effects
of PAF on the proliferation and differentiation of cultured human
keratinocytes, although keratinocyte phenotypes in this model system
are known to be affected by supplements such as calcium, BPE, and
essential fatty acids in culture conditions (Boyce and Ham, 1983, 1985;
Marcelo et al, 1992, 1994).
Under the conditions used, PAF inhibited the proliferation of
cultured keratinocytes at a growth phase (Fig 4). WEB 2086, a specific
PAFR antagonist, blocked the action of PAF, indicating that PAF
affects keratinocyte proliferation via specific PAFR. On the other hand,
WEB 2086 alone had no effects on keratinocyte proliferation, suggesting
that the endogenous production of PAF in keratinocytes at a growth
phase is not functionally sufficient to affect proliferation under these
conditions. Our findings raised a possibility that when a significant
amount of PAF is released from infiltrated blood cells, it may inhibit
keratinocyte proliferation.
Recently, we reported that PAFR-overexpressing transgenic mice
showed abnormalities in the skin (Ishii et al, 1997). In contrast to the
normal mice, the transgenic mice had a large number of pigmented
cells and fibroblasts in the dermis, and also acanthosis was evident in
the epidermis. At present, we do not have a good explanation for
these seemingly opposite directional effects of PAF in terms of
keratinocyte proliferation. Several groups including us, however,
reported the dual growth regulatory effects of PAF (stimulatory and
inhibitory), depending on cell type, concentration of PAF, and acting
points on the cell cycle (Behrens and Goodwin, 1990; Leprince et al,
1991; Roth et al, 1996; Kume and Shimizu, 1997). Not only the
degree of PAFR expression but also the amount of PAF synthesized
or released in situ might be important to explain the in vivo phenomena
in terms of keratinocyte proliferation and differentiation. Further studies
of PAFR transgenic mice will clarify roles of PAF and PAFR on cell
proliferation.
During the process of keratinocyte differentiation, PAF itself had no
effect on the cornified envelope formation of cultured keratinocytes
(Fig 5). In contrast, WEB 2086 alone stimulated keratinocyte
cornification concentration dependently (Fig 6), and exogenously
added PAF blocked the effect of WEB 2086 (Fig 5). The similar
results were obtained with other PAFR antagonists with different
chemical moieties such as SM-10661, CV-3988, U66985, and FR-
49175. These results suggest that keratinocytes produce PAF in an
autocrine manner during the process of differentiation, and that PAFR
antagonists compete with PAF. The effects of WEB 2086 on the
differentiation, in contrast to the lack of effects on proliferation during
the growth phase (compare Fig 4 with Fig 5), indicate that the amount
of PAF produced in keratinocytes differs depending on the phases of
the differentiation. Moreover, in situ mRNA hybridization analyses
showed that the expression of PAFR mRNA was more intense in
differentiating cells than in the basal cells of the epidermis (Fig 1a).
These findings suggest that PAF might be an intrinsic regulator on the
later process of keratinocyte differentiation mediated by specific PAFR.
On the basis of the above findings, keratinocytes may be induced
to parakeratosis when keratinocytes and/or infiltrated blood cells release
significant amounts of PAF. In fact, PAF was isolated from the
lesional scales of psoriasis with anomalous keratinocyte proliferation
VOL. 110, NO. 6 JUNE 1998 PAF ACTIONS AND RECEPTOR EXPRESSION IN SKIN 893
and keratinization (Mallet and Cunningham, 1985). Anti-psoriatic
drugs such as nitrogen mustard and dexamethasone inhibit PAF
biosynthesis of cultured human keratinocytes stimulated with calcium
ionophores (Liu et al, 1994). These reports suggest that PAF is involved
in the pathogenesis of psoriasis, which is consistent with our findings
that PAF inhibited keratinocyte differentiation.
In conclusion, we demonstrate here that PAFR mRNA is highly
expressed in keratinocytes, and that PAF is involved in the regulation
of proliferation and differentiation of the cells. PAF itself had no
effects on keratinocyte differentiation, but reversed the differentiation-
stimulating activities of WEB 2086 or other PAF antagonists (Figs 5,
6). The finding suggests the autocrine role of PAF in inhibiting
keratinocyte differentiation. Further studies are needed to clarify
how PAF production is regulated, and how PAF is associated with
keratinocyte proliferation and differentiation in normal skin and skin
diseases.
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